Publications

Below is a select list of publications from the Clark lab:

Erickson CM, Clark LR, Umucu E, Vo NH, Volgman AS, Chin NA, Ketchum FB, Jones CH, Gleason CE, Aggarwal NT. (2022). Cardiology clinic patient attitudes toward and potential personal utility of genetic testing: Findings from a unique multiracial clinical sample. Journal of Genetic Counseling, in press. 2022 Apr 23. doi: 10.1002/jgc4.1573. PMID: 35460578.

Ketchum FB, Erickson CM, Chin NA, Gleason CE, Lambrou NH, Benton SF, Clark LR. (2022). What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer’s Disease Biomarker Research? Journal of Alzheimers Disease, in press. 2022 Apr 16. doi: 10.3233/JAD-215521. PMID: 35466937.

Ketchum, F.B., Chin, N.A., Grill, J., Gleason, C.E., Erickson, C., Clark, L.R., Paulsen, J.S., Kind, A.J.H. (2022). Moving beyond disclosure: Stages of care in preclinical Alzheimer’s disease biomarker testing. Alzheimer’s & Dementia, in press. 2022 Jan 11. doi: 10.1002/alz.12620.

Erickson C.M., Chin N.A., Ketchum F.B., Jonaitis, E.M., Zuelsdorff, M., Gleason, C.E., Clark, LR. (2022). Predictors of willingness to enroll in hypothetical Alzheimer’s disease biomarker studies that disclose results. Alzheimer’s disease and Associated Disorders, in press. doi: 10.1097/WAD.0000000000000490. Published 2/4/2022. PMID: 35125399.

Erickson CM, Chin NA, Coughlin DM, Conway CE, Rosario HL, Johnson SC, Clark LR (2021). Virtual disclosure of preclinical Alzheimer’s biomarkers: Preliminary experiences. J Am Geriatr Soc. 2021 Jul;69(7):2044-2047. doi: 10.1111/jgs.17184. Epub 2021 May 7.

Erickson CM, Chin NA, Johnson SC, Gleason CE, & Clark LR (2021). Disclosure of preclinical Alzheimer’s disease biomarker results in research and clinical settings: Why, how, and what we still need to know. Alzheimers Dementia (Amst). 2021 Feb 20;13(1):e12150. doi: 10.1002/dad2.12150. eCollection 2021.

Clark, L.R., Norton, D., Berman, S., Johnson, S.C., Bendlin, B.B., Wieben, O., Turski, P., Carsson, C., Asthana, S., Gleason, C.E., Johnson, H.M. (2019). Association of cardiovascular and Alzheimer’s disease risk factors with intracranial arterial blood flow in whites and African Americans. Journal of Alzheimer’s Disease, 72(3), 919-929. doi: 10.3233/JAD-190645.

Clark, L.R., Koscik, R.L., Allison, S.L., Berman, S.E., Norton, D.N., Carlsson, C.M., Betthauser, T., Bendlin, B.B., Christian, B.T., Chin, N., Asthana, S., & Johnson, S.C. (2019). Hypertension and obesity moderate the relationship between beta-amyloid and cognitive decline in midlife. Alzheimer’s & Dementia, 2019 Mar;15(3):418-428.doi: 10.1016/j.jalz.2018.09.008. Epub 2018 Oct 25.

Clark, L.R., Berman, S.E., Norton, D., Koscik, R.L., Jonaitis, E., Blennow K., Bendlin, B.B., Asthana, S., Johnson, S.C., Zetterberg, H., Carlsson, C.M. (2018). Age-accelerated cognitive decline in asymptomatic adults with CSF β-amyloid. 2018 Apr 10;90(15):e1306-e1315. doi: 10.1212/WNL.0000000000005291. Epub 2018 Mar 9.

Clark, L.R., Koscik, R.L., Nicholas, C.R., Okonkwo, O.C., Engelman, C.D., Bratzke, L.C., . . . Johnson, S.C. (2016). Mild cognitive impairment in late middle age in the Wisconsin Registry for Alzheimer’s Prevention (WRAP) study: Prevalence and characteristics using robust and standard neuropsychological normative data. Archives of Clinical Neuropsychology. 2016 Nov 22;31(7):675-688. doi: 10.1093/arclin/acw024.

Clark, L.R., Racine, A.M., Koscik, R.L., Okonkwo, O.C., Engleman, C.D., Carlsson, C.M., . . . Johnson, S.C. (2016). Beta-amyloid and cognitive decline in late middle age: Findings from the WRAP study. Alzheimer’s & Dementia, 12, 805-814, doi:10.1016/j.jalz.2015.12.009.